Strides Pharma Science Limited has successfully closed the USFDA inspection of its flagship formulations facility in Bengaluru, receiving a Voluntary Action Indicated (VAI) classification. This resolves all 5 observations from the May 2026 inspection, removing a key regulatory overhang. Key Highlights: Regulatory Win: The swift conversion of a Form 483 to a closed VAI status within three months underscores the company’s robust quality management systems, ensuring uninterrupted manufacturing and future ANDA approvals for the US, Europe, and Australia. Strong Q1 FY27 Financials: Consolidated revenue grew 13% YoY to ₹1,265.4 crore, with Ex-US markets surging 17% YoY to ₹587.5 crore. EBITDA stood at ₹229.8 crore (+5.4% YoY), absorbing a ₹13.1 crore geopolitical cost impact. Strategic Liquidity: The company unlocked ₹100 crore by divesting a majority stake in its captive GCC subsidiary, Pivot Path, to an Ascent Capital-led consortium. This boosted reported PAT to ₹165.5 crore (vs. operational PAT of ₹123.1 crore) while strengthening the balance sheet. Strategic Outlook: This regulatory green light is a critical operational milestone for Strides, as the Bengaluru site is the backbone of its regulated formulations division. Coupled with strong top-line growth and improved liquidity from the GCC divestment, the company is well-positioned to confidently execute its US product launch timelines and sustain margin resilience in a complex global environment.

STAR

#StockInNews#WatchOutFor

904 likes·56 comments